Novel Hsp90 inhibitor shows activity in slowing KRAS-mutant NSCLC tumor cell growth. Use with traditional chemotherapy resulted in increased cancer cell death. Phase 2b/3 trial combined with docetaxel under way. SAN DIEGO — The investigational drug ganetespib, a synthetic second-generation Hsp90...
Tue, Jan 10 2012
Filed under: Filed under: Press Releases, Research, Treatment, Conference, Cancer, Media Materials, AACR, lung cancer, American Association for Cancer Research, genetics, KRAS, non-small cell lung cancer, AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer, International Association for the Study of Lung Cancer, IASLC, NSCLC, Jaime Acquaviva, David A. Proia, ganetespib, clinical trials, Hsp90 inhibitor